/주식/BNTC
BNTC

BNTC

USD

Benitec Biopharma Inc. Common Stock

$15.710+0.380 (2.479%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$15.330

고가

$15.770

저가

$14.550

거래량

0.13M

기업 기본 정보

시가총액

412.4M

산업

생명공학

국가

United States

거래 통계

평균 거래량

0.05M

거래소

NCM

통화

USD

52주 범위

저가 $9.1현재가 $15.710고가 $17.15

관련 뉴스

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma with a Buy and raises the price target from $28 to $35.

더 보기
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35
Analyst Upgrades

Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22

Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $20 to $22.

더 보기
Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22
GlobeNewswire

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted

더 보기
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
GlobeNewswire

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based

더 보기
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
GlobeNewswire

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines

더 보기
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기